Assessment of a novel chemical entity (TRV 1387) in the treatment of tau-related neuropathology and behavioral impairment in a transgenic mouse model of Alzheimer’s disease

The onset of symptoms in Alzheimer’s Disease, Picks disease, progressive supranuclear palsy and cortical basal degeneration are connected to the formation of insoluble deposits of the tau protein in the brain, also known as neurofibrillary tangles (NFT). The Treventis Corporation has developed new chemicals that are designed to prevent the formation of NFT, which may be useful for treating Alzheimer’s disease. Genetically modified mice that develop NFTs in their brains have been developed as animal models of Alzheimer’s disease, and are therefore useful to test the effects of novel treatments. This experiment will determine whether the novel chemical TRV 1387 can reduce the amount of brain pathology and behavioural impairments in a mouse model of Alzheimer’s disease. This research will benefit the Treventis Corporation, by determining whether these novel chemicals are effective and thus potentially useful for humans with Alzheimer’s disease.

Faculty Supervisor:

Dr. Denis Gingras


Aimee A. Wong


Treventis Corporation





Dalhousie University



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects